Tags : COMET Study

Biotech Clinical Trials

Sanofi Report Results of Avalglucosidase alfa in P-III COMET Study

Shots: The P-III COMET study involves assessing avalglucosidase alfa (20 mg/kg) vs alglucosidase alfa (SOC, 20 mg/kg) IV infusion q2w for 49 wks. After 49 wks., patients previously receiving SOC switched to avalglucosidase alfa for the ongoing open-label treatment portion of the study Results: met its 1EPs i.e. demonstrating non-inferiority in improving respiratory function, FVC […]Read More